Mammalian and bacterial nitric oxide synthase inhibitors
Disclosed are compounds that are shown to inhibit the biological activity of nitric oxide synthases (NOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. Because the disclosed compounds are shown to inhibit the activity of nitric oxide synthases (NOSs), the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with NOS activity.
1. A compound of a formula
or a salt or solvate thereof, wherein
R 1 is hydrogen or alkyl;
L 1 is a divalent linker-selected from methylene and substituted methylene, said substituents selected from hydroxy, amino, aminoalkyl, and combinations thereof;
X is selected from CH, CR 3 and N;
L 2 is a divalent linker selected from alkylene, alkylamino, cycloalkylamino, and morpholino;
R 2 is selected from hydrogen, amino, alkyl-substituted amino, alkoxy, and optionally-substituted cycloalkyl, heterocycloalkyl, phenyl, and pyridinyl, said substituents selected from amino, halo, and alkyl, provided that if L 2 is alkylene then R 2 is amino or alkyl-substituted amino; and
R 3 is selected from alkyl, halo, haloalkyl, cyano, amino, and aminoalkyl.
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. The compound of claim 1 , wherein L 2 is selected from —(CH 2 ) m —, —NH(CH 2 ) m — and —N(R)(CH 2 ) m —, where m is 0-4; R is selected from alkyl and cycloalkyl; and R 2 is selected from amine, alkyl-substituted amine, cycloalkyl-substituted amine, and optionally-substituted phenyl and pyridinyl.
4. The compound of claim 1 wherein L 2 is selected from —CH 2 NH(CH 2 ) 2 —, —CH 2 N(CH 3 )(CH 2 ) 2 —, —CH 2 NH(CH 2 ) 3 —, —CH 2 NHCH 2 —, and —N(CH 3 )(CH 2 ) 2 —.
5. The compound of claim 1 wherein R 2 is alkyl-substituted amino.
6. The compound of claim 4 wherein L 2 is selected from —CH 2 NH(CH 2 ) 2 —, —CH 2 N(CH 3 )(CH 2 ) 2 —, —CH 2 NH(CH 2 ) 3 —, —CH 2 N(CH 3 )(CH 2 ) 3 —, —CH 2 NHCH 2 — and —N(CH 3 )(CH 2 ) 2 —.
7. The compound of claim 1 wherein L 2 is —NH(CH 2 ) m — and m is selected from 1 and 2; and R 2 is selected from optionally substituted pyridinyl and phenyl.